Table 2.
Age (years) sex |
Underlying disease | Type of influenza virus | ADAMTS13 activity | ADAMTS13 inhibitor | Treatment | Outcome | References |
---|---|---|---|---|---|---|---|
35 F | None | A | low | positive | PE Corticosteroid | Improvement | (10) |
68 F | None | A | <0.5% | positive | PE Corticosteroid | Death | (11) |
27 M | None | A (H1N1) | N/A | N/A | PE Corticosteroid | Improvement | (12) |
12 unknown | None | A (H1N1) | N/A | N/A | PE | Improvement | (14) |
18 F | Atypical HUS | A (H1N1) | 37% | negative | PE | Improvement | (14) |
11 M | Hereditary heterozygous PS deficiency | A (H1N1) | 68% | negative | PE Corticosteroid | Improvement | (15) |
44 M | SSc | B | 60.3% | negative | PE ACEi | Improvement | Present Case |
ACEi: angiotensin-converting enzyme inhibitor, ADAMTS13: a disintegrin and metalloprotease with thrombospondin type-1 repeats: member 13, HUS: hemolytic uremic syndrom, N/A: not assessed, PE: plasma exchange, SSc: systemic sclerosis, TMA: thrombotic microangiopathy